Advances in pneumococcal antibiotic resistance. (October 2013)

• Record Type: Journal Article
• Authors: Song, Jae-Hoon
• Is Part Of: Expert review of respiratory medicine. Volume 7:Number 5(2013)
• Page Start: 491
• Page End: 498
• Publication Date: 2013-10
• Subjects: macrolide resistance -- multidrug resistance -- penicillin resistance -- pneumococcal conjugate vaccine -- serotype 19A -- Streptococcus pneumoniae; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Diseases -- Treatment -- Periodicals; 616.2005
• DOI: 10.1586/17476348.2013.816572
• Languages: English
• ISSNs: 1747-6348

Abstract

Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV). Particularly, among various types of antimicrobial resistance, macrolide resistance has most remarkably increased in many parts of the world, which has been reported to be >70% among clinical isolates from Asian countries. Penicillin resistance has dramatically decreased among nonmeningeal isolates due to the changes in resistance breakpoints, although resistance to other β-lactams such as cefuroxime has increased. Multidrug resistance became a serious concern in the treatment of invasive pneumococcal diseases, especially in Asian countries. After PCV7 vaccination, serotype 19A has emerged as an important cause of invasive pneumococcal diseases which was also associated with increasing prevalence of multidrug resistance in pneumococci. Widespread use of PCV13, which covers additional serotypes 3, 6A and 19A, may contribute to reduce the clonal spread of drug-resistant 19A pneumococci.